looking at pfizer, merck, gilead and cellgene, on the target side, companies as big as alexion and insided tesaro. we seen tesaro stock down as they put out plans to launch their new cancer drug. people take that to mean maybe they won't be a potential target. biotech earnings check in week. they are saying it could be a mixed bag in terms of performance, of folks who could beat, looking at potentially alexion, cellgene where they think amgen comes in. on the positive side. you haven't seen negative pre announcements, for these companies, meaning it could go well. there is seasonal weakness. on the positive sidesh that means from an investment standpoint, drug price increases are still happening, even amid this, 40 in this year versus 23 in 2016. they seem like they're accelerating right now. >> maybe they're smaller? maybe they're smaller. however, there was a really interesting no doubt from credit suisse showed it came from drug price increases. >> all were drug price increase? >> their growth 8.7 billion in growth. 100% drug increases. >> staggering. >> meg mentioned tsr. >> tesora. >